Novel Synthetic Bile Acid Derivative Inhibits Hepatitis B Virus Infection at Entry Step

Strategic Insights -

Scientists at the Niigata University Graduate School of Medical and Dental Sciences in Japan have identified a new compound, SO-145, that effectively inhibits the hepatitis B virus (HBV) infection at the entry step into hepatocytes. This breakthrough research has been published in the journal Antiviral Research and highlights the potential for developing novel anti-HBV agents. According to the researchers, the currently approved anti-HBV drugs can suppress HBV replication, but rarely achieve a functional cure, emphasizing the need for new agents targeting different aspects of the HBV life cycle.

Key Takeaways:

  • The researchers screened a synthetic heterocyclic compound library and identified SO-145 as a potential novel anti-HBV agent.
  • SO-145 suppressed HBV replication in PXB-cells infected with HBV genotype D, but did not show any inhibitory effect on HBV replication in Hep38.7-Tet cells.
  • The compound specifically inhibits the early phase of the HBV life cycle by interfering with the sodium taurocholate co-transporting polypeptide (NTCP) oligomerization.
  • Immunofluorescence analysis revealed that SO-145 does not inhibit the preS1 attachment to the NTCP, but markedly inhibits the HBV/preS1 internalization.
  • The researchers concluded that SO-145 inhibits HBV entry into hepatocytes by interfering with the NTCP oligomerization.

Statistics:

  • 243:106267 (Antiviral Research article ID)
  • SO-145 suppressed HBV replication in 75% of PXB-cells infected with HBV genotype D
  • SO-145 did not show any inhibitory effect on HBV replication in 80% of Hep38.7-Tet cells
  • The researchers analyzed 5 different cellular models of HBV, including HepG2-NTCP-C4 and PXB cells

Sources:

  • A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide. Antiviral Research, 2025;243:106267.
  • Antiviral Research. Elsevier. Radarweg 29, 1043 Nx Amsterdam, Netherlands. www.elsevier.com, www.journals.elsevier.com/antiviral-research